St. Jude's current COO to succeed Daniel Starks as company CEO in 2016

St. Jude ($STJ) COO Michael Rousseau will become its CEO starting Jan. 1, 2016. He will replace retiring CEO Daniel Starks. "Over the past 16 years, I have had the privilege of working alongside Dan to change the company from being largely dependent on valves and CRM (cardiac rhythm management) devices to being an industry leader with a diverse disease state management portfolio," said Rousseau. "With our recent acquisitions and our strong, robust product pipeline, I am focused on remaining steadfast in our commitment to innovation and growth so that we can continue Dan's legacy of bringing the right solutions at the right time to our customers, while improving patient outcomes and reducing health care costs." Rousseau joined the company in 1999 as the senior vice president of cardiac rhythm management global marketing. In 2008, he was promoted to group president and in 2014 to chief operating officer. Starks will become the executive chairman of the St. Jude board of directors upon his retirement from the CEO post. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.